(XERS) Xeris Biopharma Holdings, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(XERS) Xeris Biopharma Holdings, Inc. Complete Analysis Pack
Xeris Biopharma’s Business Model, Simplified
Unlock the full strategic blueprint behind Xeris Biopharma Holdings, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, builds partnerships, and monetizes its specialty pharmaceutical portfolio. Perfect for investors, analysts, and strategists who want a clearer view of the company’s growth engine.
Partnerships
Specialty pharmacies
Specialty pharmacies are key to Xeris Biopharma Holdings, Inc. because they fulfill injectable and rare-disease therapies like Gvoke, Keveyis, and Recorlev. They also handle refill coordination and adherence tracking, which helps keep patient access steady and supports repeat use.
Wholesale distributors
Wholesale distributors move Xeris Biopharma Holdings, Inc. products from factory supply into pharmacies and health systems, and they sit inside the order-to-cash flow for prescription biopharma. In the U.S., the three largest distributors, McKesson, Cencora, and Cardinal Health, handle about 90% of drug distribution, so reliable coverage is key to keeping products available.
Contract manufacturers
Xeris Biopharma Holdings, Inc. relies on contract manufacturers for sterile fill-finish and finished dosage production, which is critical for injectable and oral specialty medicines that must meet tight quality specs. In 2025, the Company supported 3 commercial products, so batch consistency, capacity, and supply continuity stay central to this partnership.
CROs and clinical sites
CROs and investigator sites let Xeris Biopharma Holdings, Inc. run development and post-marketing studies without building every trial in-house. They are key for label expansions and new pipeline assets, and they help Xeris move programs faster across multiple study sites.
- Support label-expansion trials.
- Run post-marketing studies.
- Advance pipeline assets.
Patient support and hub vendors
Patient support and hub vendors help Xeris Biopharma Holdings, Inc. speed access by handling benefits checks, prior authorization, patient onboarding, and co-pay support for specialty therapies. That matters in high-friction reimbursement settings, where delays can block first fills and slow adoption of products like Gvoke, Recorlev, and Keveyis.
- Benefits verification
- Prior authorization
- Co-pay and access help
- Faster patient start
Xeris Depends on Key Partners to Keep Its 3 Drugs Moving
Xeris Biopharma Holdings, Inc. depends on specialty pharmacies, the big three U.S. distributors that handle about 90% of drug distribution, and contract manufacturers to keep Gvoke, Keveyis, and Recorlev moving through the channel. In 2025, the Company had 3 commercial products, so supply continuity and access partners stayed central.
| Partner | Role | Key data |
|---|---|---|
| Specialty pharmacies | Fills, refills, adherence | Supports repeat use |
| McKesson, Cencora, Cardinal Health | Wholesale distribution | About 90% U.S. share |
| Contract manufacturers | Sterile fill-finish | 3 products in 2025 |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas of Xeris Biopharma Holdings, Inc. covering its 9 blocks, strategy, and market-facing operations.
Customizable Excel Spreadsheet
Quickly spot how Xeris Biopharma’s model eases patient and provider pain points in a one-page, editable snapshot.
Reference Sources
Provides a traceable source trail for Xeris Biopharma Holdings, Inc. that strengthens credibility and speeds investor due diligence.
Activities
Commercialize 3 marketed products
Xeris Biopharma Holdings, Inc. commercializes 3 marketed products—Gvoke, Keveyis, and Recorlev—through promotion, field support, and access management. Sustained prescription growth depends on converting coverage into use and keeping each brand visible in the field.
Develop XeriSol and XeriJect
Xeris Biopharma Holdings, Inc. uses its XeriSol and XeriJect platforms to develop stable liquid and ready-to-use formulations, a core part of its differentiation strategy. These platforms have helped support 3 commercial products, including Gvoke, Recorlev, and Keveyis, while also enabling new product candidates and life-cycle extensions that can reduce reformulation risk and speed development.
Run clinical and regulatory programs
Xeris Biopharma Holdings, Inc. runs clinical development and regulatory filings to expand existing uses and support new product approvals; as of 2024, it had 3 marketed products, so label expansion can directly widen each product’s commercial reach. These programs turn trial data into FDA submissions and new therapeutic options.
Manage manufacturing and supply chain
Xeris Biopharma Holdings, Inc. must keep reliable supply for its commercial products and pipeline materials, because sterile and specialty-dose medicines depend on tight quality control, vendor oversight, and inventory planning. This activity protects product availability, supports FDA-grade compliance, and helps reduce stockout risk across a complex outsourced manufacturing base.
- Secure steady drug substance and components
- Audit vendors and manage quality
- Plan inventory for launch and demand swings
- Protect supply for sterile, specialty-dose products
Medical affairs and pharmacovigilance
Xeris Biopharma Holdings, Inc. runs medical affairs and pharmacovigilance to track safety, medical information, and post-marketing experience across its 3 approved therapies in endocrine and rare-disease care. Medical affairs also supports physician education and evidence generation, which matters because these therapies keep adding real-world safety data after launch.
- Monitors post-marketing safety
- Supports physician education
- Builds real-world evidence
- Critical in rare-disease use
Xeris: 3 Products, Two Platforms, One Fast Growth Push
Xeris Biopharma Holdings, Inc. key activities center on selling 3 marketed products, advancing its XeriSol and XeriJect platforms, and running clinical, regulatory, and post-marketing work. The focus is fast: turn stable liquid delivery into approvals, coverage, and prescription growth.
| Key activity | Current fact |
|---|---|
| Commercialization | 3 marketed products |
| Platform R&D | XeriSol and XeriJect |
| Safety | Post-marketing monitoring |
Full Version Awaits
Business Model Canvas
This Xeris Biopharma Holdings, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase. It is not a mockup or sample—what you see here is a direct snapshot of the final file. Once you complete your order, you’ll get the same professionally formatted content, ready to use right away.
Resources
Gvoke, Keveyis, Recorlev
Gvoke, Keveyis, and Recorlev are Xeris Biopharma Holdings, Inc.’s core revenue engines; in 2025, the company said these marketed brands drove its commercial base and product sales. They serve three distinct specialty markets: severe hypoglycemia, primary periodic paralysis, and endogenous Cushing’s syndrome.
XeriSol platform
XeriSol is Xeris Biopharma Holdings, Inc. proprietary formulation platform for liquid and injectable drugs, and it underpins products like Gvoke and Recorlev. It helps replace harder-to-use legacy formulations with ready-to-use options that can improve convenience, dosing, and patient usability.
XeriJect platform
XeriJect is Xeris Biopharma Holdings, Inc.'s proprietary injectable formulation and delivery platform, and it is a core technical moat behind product design and development. As of 2025, it supports the company’s 3 marketed products, helping Xeris turn formulation know-how into protected, harder-to-copy injectable assets.
Regulatory approvals and IP
Xeris Biopharma Holdings, Inc. key resources are its 3 FDA-approved product labels—Gvoke, Recorlev, and Keveyis—plus its patent estate and device know-how. These assets protect commercialization, support market exclusivity, and help extend the life of each franchise through line extensions and new indications.
- 3 approved product labels
- Patent-backed exclusivity
- Supports expansion
Specialty commercial infrastructure
Xeris Biopharma Holdings, Inc. depends on specialty commercial infrastructure: sales, access, reimbursement, and medical teams that support 3 marketed orphan and specialty products. These functions help reach prescribers, secure payer coverage, and guide patients through start-of-therapy, which is vital in niche markets with small addressable populations.
- Sales teams drive prescriber reach
- Access teams support payer coverage
- Reimbursement teams reduce friction
- Medical teams support clinical use
Xeris’ 3 Brands and Formulation Platforms Power 2025 Revenue
Xeris Biopharma Holdings, Inc. key resources are its 3 FDA-approved brands—Gvoke, Keveyis, and Recorlev—plus XeriSol and XeriJect, its proprietary formulation platforms. In 2025, these assets anchored the company’s specialty revenue base and supported 3 marketed products.
| Resource | 2025 role |
|---|---|
| 3 brands | Revenue base |
| XeriSol/XeriJect | Core moat |
Value Propositions
No-reconstitution glucagon
Gvoke gives Xeris Biopharma Holdings, Inc. a ready-to-administer liquid glucagon for severe hypoglycemia, removing the mixing step that slows older rescue kits. The product is sold in 0.5 mg and 1 mg doses, and Xeris reported Gvoke net sales of $67.9 million in 2025, showing demand for easier emergency use.
Primary periodic paralysis therapy
Keveyis is Xeris Biopharma Holdings, Inc.'s targeted therapy for hyperkalemic, hypokalemic, and related forms of primary periodic paralysis, a rare neuromuscular disorder that affects about 1 in 100,000 people. As the only FDA-approved treatment in this niche, it gives specialists a focused option for an underserved patient group.
Cushings syndrome treatment
Xeris Biopharma Holdings, Inc.'s Recorlev gives adults with endogenous hypercortisolemia in Cushing's syndrome an approved oral option in a rare disorder affecting about 40 to 70 people per million. That adds a specialty-disease choice where treatment options are limited and care is highly specialized.
Proprietary formulation technology
Xeris Biopharma Holdings, Inc. uses 2 proprietary formulation platforms, XeriSol and XeriJect, to support differentiated product design. They can improve usability, stability, and delivery, and the same base technology can be reused across multiple drugs, so the value is platform-wide, not tied to one asset.
- 2 platforms: XeriSol and XeriJect
- Better usability and stability
- Reusable across more than one drug
Commercial-stage specialty portfolio
Xeris Biopharma Holdings, Inc. pairs 3 marketed products with a pipeline, so it has near-term revenue plus upside from new launches. Its portfolio spans endocrinology, neurology, and gastroenterology, with products like Gvoke and Recorlev already in market.
- 3 marketed products support current sales
- Pipeline adds future growth options
- Covers endocrinology, neurology, gastroenterology
Xeris’ Gvoke Drives 2025 Sales with Ready-to-Use Rescue Glucagon
Xeris Biopharma Holdings, Inc. sells specialty medicines that solve urgent, hard-to-treat problems: Gvoke simplifies rescue glucagon use, Keveyis serves a rare paralysis niche, and Recorlev treats endogenous Cushing's syndrome. In 2025, Gvoke net sales reached $67.9 million, showing demand for easier, ready-to-use care.
| Asset | Value proposition | 2025 data |
|---|---|---|
| Gvoke | Ready-to-use glucagon | $67.9M sales |
Customer Relationships
Physician education support
Xeris Biopharma Holdings, Inc. uses physician education to help specialists use its 3 marketed therapies correctly across endocrinology, neurology, and gastroenterology. That support matters because Xeris reported net sales growth in 2025, and better prescribing confidence can help protect adoption.
Reimbursement navigation
Xeris Biopharma Holdings, Inc. uses reimbursement navigation to help patients and providers manage coverage, prior authorization, and benefits checks, which matters in specialty biopharma where access can slow starts. With 3 commercial products in the portfolio, this hands-on support helps cut friction at the point of prescription and improve fill rates.
Patient assistance programs
Patient assistance programs help Xeris Biopharma Holdings, Inc. cut out-of-pocket friction, which can speed treatment starts and support refill continuity in specialty drugs. For Xeris Biopharma Holdings, Inc., this matters across long-term therapies where adherence drives persistence and revenue stability.
Field-based account management
Field-based account management keeps Xeris Biopharma Holdings, Inc. sales teams close to clinics, prescribers, and access staff, which matters for rare-disease and specialty products that need ongoing education and clean order flow. In 2025, Xeris Biopharma Holdings, Inc. reported $221.8 million in product revenue, and this kind of hands-on coverage helps protect access and support script conversion.
- Clinic education
- Access support
- Order flow follow-up
Medical information response
Xeris Biopharma Holdings, Inc. uses medical information response to give healthcare professionals timely, labeled, evidence-based product and safety answers. That keeps engagement compliant and builds trust when they need clear guidance on use, risks, and monitoring.
- Timely product support
- Labeled, evidence-based replies
- Safer, compliant HCP engagement
Xeris’ hands-on access support aims to keep 2025 sales growing
Xeris Biopharma Holdings, Inc. keeps relationships close and hands-on: physician education, reimbursement help, patient assistance, and field account support all aim to reduce access friction and keep 2025 product sales moving. The company reported $221.8 million in product revenue in 2025, so every extra fill and refill matters.
| Channel | 2025 signal |
|---|---|
| HCP education | 3 marketed therapies |
| Access support | Coverage and PA help |
| Patient aid | Adherence support |
Channels
Specialty pharmacy channel
Specialty pharmacies are a key route for Xeris Biopharma Holdings, Inc. therapies, especially high-touch products like Recorlev and Keveyis. They handle dispensing, refill coordination, and access support, which helps keep treatment starts and refills moving for patients who need close follow-up.
Wholesale distribution
Wholesale distribution is Xeris Biopharma Holdings, Inc.'s main route into the prescription drug supply chain: large wholesalers move product from manufacturing to pharmacies, hospitals, and health systems. In the U.S., 3 national players - McKesson, Cencora, and Cardinal Health - dominate this channel, which is standard for commercial biopharma products.
Prescriber office sales
Xeris Biopharma Holdings, Inc. uses field reps and account teams to sell directly to specialist prescribers, with a clear focus on endocrinologists, neurologists, and other niche clinicians. This matters for focused patient groups, because one targeted office call can drive adoption for products that treat rare or hard-to-manage conditions.
Patient support hubs
Patient support hubs are a key access channel for Xeris Biopharma Holdings, Inc.: they handle enrollment, benefits checks, and onboarding, which can cut friction for specialty-drug starts. For Xeris, this matters because products like Gvoke, Recorlev, and Keveyis depend on fast insurance approval and clean handoffs to shorten time to therapy.
Enroll patients fast
Run benefits checks
Guide onboarding steps
Reduce therapy delays
Medical and digital engagement
Xeris Biopharma Holdings, Inc. uses websites, online resources, and remote medical engagement to extend product education and patient support across its 3 marketed products, so these channels reinforce field teams instead of replacing them. This mix helps reach clinicians faster and keeps support available between in-person calls.
- Web and remote tools scale product education.
- Field reps handle deeper clinical detail.
- 3 marketed products widen channel use.
Xeris Uses a Multi-Channel Model to Expand Access
Xeris Biopharma Holdings, Inc. sells through 4 main channels: specialty pharmacies, national wholesalers, field sales, and patient support hubs. The model fits its 3 marketed products, where access work and clinician education matter as much as dispensing.
Wholesalers move product into U.S. pharmacies and health systems, while specialty pharmacies and hubs handle benefits checks, onboarding, and refills. Web and remote tools extend that reach between visits.
| Channel | Role | Data |
|---|---|---|
| Specialty pharmacies | Dispense and refill support | 3 marketed products |
| Wholesalers | National distribution | 3 dominant U.S. players |
Customer Segments
Adults with severe hypoglycemia risk
Adults with severe hypoglycemia risk are a core Gvoke segment: people with diabetes and the caregivers who need a fast rescue option during emergencies. In the U.S., 38.4 million people have diabetes, and rapid, easy-to-use glucagon matters most when confusion, seizure, or unconsciousness makes oral treatment impossible.
Primary periodic paralysis patients
Keveyis serves patients with hyperkalemic, hypokalemic, and related primary periodic paralysis, a rare neuromuscular disorder affecting about 1 in 100,000 people. Demand is concentrated in neuromuscular specialists and expert centers, so each confirmed patient matters a lot for Xeris Biopharma Holdings, Inc.
Adults with Cushings syndrome
Recorlev targets adults with endogenous hypercortisolemia from Cushing's syndrome, a rare specialty-disease segment typically managed by endocrinology specialists. Cushing's syndrome affects about 40 to 70 people per million, so Xeris Biopharma Holdings, Inc. serves a narrow, high-need patient pool with a defined referral path.
Endocrinologists and neurologists
Endocrinologists and neurologists are Xeris Biopharma Holdings, Inc. key professional buyers: endocrinologists drive Gvoke and Recorlev, while neurologists are the main prescribers for Keveyis. In FY2025, that means 3 marketed products tied to 2 specialist groups, so this segment directly shapes prescription volume and portfolio sales.
- Endocrinologists: Gvoke and Recorlev
- Neurologists: Keveyis
- Primary professional customer segment
Payers and specialty pharmacies
Health plans, PBMs, and specialty pharmacies are the main gatekeepers for Xeris Biopharma Holdings, Inc. specialty drugs, because they set formulary access, prior-authorization rules, and dispensing routes that drive uptake. In 2024, specialty medicines were about 75% of U.S. drug spend but under 2% of prescriptions, so coverage calls matter a lot.
- PBMs shape formulary access
- Specialty pharmacies control dispensing
- Coverage drives demand fast
Xeris’ Specialty Drug Demand: Three Niche Markets, One FY2025 Focus
Xeris Biopharma Holdings, Inc. sells to three patient groups: adults at risk of severe hypoglycemia for Gvoke, rare periodic paralysis patients for Keveyis, and adults with endogenous Cushing’s syndrome for Recorlev. FY2025 demand is driven by specialists, mainly endocrinologists and neurologists, plus payers and specialty pharmacies that control access.
| Segment | FY2025 focus |
|---|---|
| Gvoke | Diabetes rescue |
| Keveyis | Neuromuscular rarity |
| Recorlev | Cushing’s syndrome |
Cost Structure
R&D expense
Xeris Biopharma Holdings, Inc. used about $31 million in R&D in 2024, funding formulation work, studies, and pipeline moves that support label expansion and new uses. This spend is key to broadening the product set and protecting future growth.
Sales and marketing
Sales and marketing is a material cost for Xeris Biopharma Holdings, Inc. because specialty drugs need field teams, HCP education, and launch promotion to drive prescriber adoption. In 2025, these costs sat inside SG&A, a line that is often the largest operating expense for specialty biopharma and can absorb a double-digit share of revenue as brands scale.
Manufacturing and quality
Xeris Biopharma Holdings, Inc. keeps spending on production, testing, and quality systems because sterile and specialty-dose manufacturing needs strict cGMP controls, lot release checks, and validated processes. That spend is what helps protect supply reliability and lower the risk of batch failure, which matters for an injectable portfolio where any disruption can hit revenue fast.
Access and patient support
Access and patient support adds operating cost through hub services, copay help, and reimbursement support, but these programs are what turn scripts into paid fills. For Xeris Biopharma Holdings, Inc., that cost sits inside specialty-drug commercialization and can materially affect selling expense and gross-to-net.
- Hub services raise operating spend
- Copay support drives fills
- Reimbursement help speeds access
G&A and compliance
Xeris Biopharma Holdings, Inc.'s G&A and compliance costs cover corporate, finance, legal, and regulatory work, plus SEC reporting and controls tied to public-company status. This overhead is a fixed layer across the business, so even small sales moves can still leave the cost base heavy.
- Corporate, legal, finance, compliance
- Public reporting adds overhead
- Supports the full enterprise
Xeris’ Costly Biopharma Model: R&D, SG&A, and QC Keep Spending High
Xeris Biopharma Holdings, Inc. spent about $31 million on R&D in 2024, while 2025 SG&A stayed the biggest cost block, driven by field sales, access support, and public-company overhead. Manufacturing and quality costs also stay high because sterile injectables need cGMP controls and lot release checks.
In short, Xeris Biopharma Holdings, Inc. runs a cost-heavy model: growth spend is front-loaded, and fixed compliance and support costs keep the base elevated. That mix is common in specialty biopharma, where paid fills depend on both promotion and patient access.
| Cost item | Latest data |
|---|---|
| R&D | $31M, 2024 |
| SG&A | Largest 2025 cost block |
| Manufacturing | cGMP and QC heavy |
Revenue Streams
Gvoke product sales
Gvoke net product sales are a core revenue stream for Xeris Biopharma Holdings, Inc., because the brand treats severe hypoglycemia rescue in diabetes care. In Xeris Biopharma Holdings, Inc.’s latest reported year, Gvoke contributed about $98 million in net product sales, and demand tracks diabetes prevalence plus caregiver readiness to act fast in an emergency.
Keveyis product sales
In FY2025, Keveyis product sales added to Xeris Biopharma Holdings, Inc.'s specialty rare-disease revenue, serving patients with primary periodic paralysis. Prescription demand stayed concentrated among specialist prescribers, so a small neurology base drives most volume.
Recorlev product sales
Recorlev product sales give Xeris Biopharma Holdings, Inc. a focused endocrinology revenue stream for adult Cushing syndrome, with net sales rising to about $52 million in 2024. Growth still depends on specialist awareness, payer access, and tight execution in endocrinology clinics.
Label expansion revenue
Label expansion revenue lets Xeris Biopharma Holdings, Inc. add sales by winning new indications for existing drugs, so the same commercial base can reach more patients without building a new product. This depends on clinical data and FDA approval, and it can scale fast if uptake follows the expanded label.
- New indications drive incremental sales.
- Approval risk stays high.
- Same sales force can expand reach.
New pipeline product sales
New pipeline product sales from XeriSol and XeriJect are Xeris Biopharma Holdings, Inc.'s longer-term growth engine, but they depend on R&D wins and FDA approvals. In 2025, the company had 3 marketed products, so any new launch could broaden revenue beyond the current base.
- Depends on R&D and approvals
- Built on XeriSol and XeriJect
- Expands beyond 3 marketed products
Xeris FY2025 Revenue: Gvoke Leads, Recorlev and Keveyis Follow
Xeris Biopharma Holdings, Inc. earns most revenue from Gvoke, Keveyis, and Recorlev product sales, with FY2025 demand still driven by specialist prescribing and payer access. Gvoke remains the biggest base, while Recorlev and Keveyis add focused rare-disease and endocrinology sales.
| FY2025 stream | Value |
|---|---|
| Gvoke | ~$98M |
| Recorlev | ~$52M |
| Keveyis | Specialty sales |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.